期刊文献+

赖诺普利关键中间体的合成研究 被引量:1

Synthesis of the Key Intermediates of Lisinopril
在线阅读 下载PDF
导出
摘要 以3-苯甲酰丙烯酸乙酯(BZ)和三氟乙酰赖氨酸(LA1)为原料,在三氟甲磺酸三正丁胺盐催化作用下,经迈克尔加成反应、氢化还原反应合成赖诺普利关键中间体N2-(1-乙氧羰基-3-苯丙基)-N6-三氟乙酰基-L-赖氨酸(LA2),总收率为38.8%。LA2加成物立体选择性可达到84:16。该方法具有操作简单,收率高,是一条适合工业化生产的合成路线。 The (R)-2-((R)- 1-ethoxy- 1--oxo-4-phenylbutan-2-ylamino)-6-(2,2,2-trifluoroaeetamido)hexanoic acid (LA2) was obtained by Michael addition from 3-benzoyl ethyl acrylate with (S)-2-amino--6-(2,2, 2- trifluoroacetamido) hexanoic acid in the presence of tributylamine triflate, followed by reduction with Pd/C. The ratio of S-LA/R-LA2 can reach 84:16, and the total yield is 38.8%. This synthetic route is suitable for large scale manufacture.
出处 《浙江化工》 CAS 2012年第9期15-17,6,共4页 Zhejiang Chemical Industry
关键词 赖诺普利 N-2-(1-乙氧羰基-3-苯丙基)-N-6-三氟乙酰基-L-赖氨酸 MICHAEL反应 三氟甲磺酸三正丁胺 还原 Lisinopril (R)-2-((R)- 1-ethoxy- 1-oxo-4-phenylbutan-2-ylamino) -6-(2,2,2-trifluomacetamido)hexanoic acid Michael reaction tributylamine triflate reduction
  • 相关文献

参考文献7

  • 1杨逸卫.赖诺普利的临床应用进展[J].世界临床药物,2003,24(10):629-633. 被引量:17
  • 2Kumar R, Sharma R, Bairwa K, et al. Modemdevelopment in ACE inhibitors [J]. Der Pharmacia Lettre, 2010, 2(3): 388-419.
  • 3Yu L T, Huang J L, Chang C Y, et at. Format Synthesis of the ACE Inhibitor Benazepril .HCI via an Asymmetric Aza-Michael Reaction [4. Mo]ectdes 2006, (11): 641-648.
  • 4Himeji Y U, Matsumoto A, Manabe H. Process for the preparation of 1-alkoxycarbonyl-3 -phenylpropyl derivatives: US, 6118010[P]. 2000-12-12.
  • 5Blacldock T J, Shuman R F, Butcher J W, et al. Synthesis of semisynthetic dipepfides using N-carboxyanhy- &ides and chiral induction on Raney Nickel. A method practical for large scale[J]. J. Org. Chem. 1988, 53: 836-844.
  • 6马大为,邓平.赖诺普利类化合物的前体及其合成力诘:CN.1539826[P].2004-10-27.
  • 7Keller E, Feringa B L. Ytterbium trit~te catalyzed Michael additions of ~-ketoesters in water[J]. Tetrahedron Lett, 1996, 37: 1879-1882.

二级参考文献17

  • 1唐丽霞.三种长效降压药物治疗方案的最小成本分析[J].药物流行病学杂志,2006,15(4):244-245. 被引量:5
  • 2覃韦苇,田媛,张尊建,许风国,薛志军,陈沄.赖诺普利片在健康志愿者体内的生物等效性评价[J].中国新药与临床杂志,2006,25(12):885-889. 被引量:5
  • 3张毕奎,陈本美,原海燕,朱运贵,冯胜,梁武,马宁,李焕德.人血浆中赖诺普利的液相色谱-质谱法测定及生物等效性研究[J].中国新药与临床杂志,2007,26(6):436-439. 被引量:4
  • 4Ruggenenti P;Mise N;Pisoni R.Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies[J],2003(04).
  • 5Mogensen CE;Neldam S;Tikkanen I.Randomised controlled trial of dual btockade of renin-angiotensin system in patients with hypertensionmicroatbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study[J],2000(7274).
  • 6Borghi C;Ambrosioni E.Double-blind comparison between zofenopril and Iisinopril in patients with acute myocardial infarction: results of the survival of myocardial infarction long-term evaluation-2 (SMILE-2) study[J],2003(01).
  • 7Ahmed A.Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine[J],2002(07).
  • 8Farquharson CA;Struthers AD.Gradual reactivation over time of vascular tissue angiotensin I to angiotensin I conversion during chronic lisinopril therapy in chronic heart failure,2002(05).
  • 9Sculpher M J;Poole L;Cleland J.Low doses vs high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure:a cost-effectiveness analysis based on the assessment of treatment with lisinopril and survival (ATLAS) study[J],2000(04).
  • 10Opie LH;Haus M;Commerford P J.Antihypertensive effects of anglotensin converting enzyme inhibition by lisinopril in post-transplant patients[J],2002(15).

共引文献16

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部